Evidence on primaquine
- Pharmacology
  - What’s the active metabolite?
  - Suitable drug partner?
- Safe and efficacious dose
- Safety by G6PD phenotype

Phase 1
Ex-vivo studies for efficacy and pharmacodynamics and pharmacokinetics

Phase 2
Dose escalation for safety and efficacy in high risk groups

Phase 3
Community trials with surrogate marker endpoints

Phase 4
Determine safety in pregnancy through review of primaquine in pregnancy in countries using primaquine

Common endpoints

Unsafe in G6PD—need to develop PoC test for phenotype

Goal
Safe and efficacious dose for mass drug administration alone or in combination

Drug supply and regulation
Identify stakeholders
Inclusion of stakeholders in road map
Implemented

Alternatives
Development of gametocytocidal drugs, e.g., tafenoquine and methylene blue
Product pipeline moving